Efficacy/Safety of Talazoparib or Physician’s Choice of Therapy in US Patients with HER2-Negative Germline BRCA1/2-Mutated Locally Advanced/Metastatic Breast Cancer (EMBRACA)

November 2019 Vol 10, No 11
Sami Diab, MD
University of Colorado Cancer Center, Aurora, CO
Hope S. Rugo, MD
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Lida A. Mina, MD
Banner Health, Gilbert, AZ
Shannon Puhalla, MD
University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA
Reshma Mahtani, DO
Sylvester Cancer Center, Deerfield Beach, FL
N. Lynn Henry, MD, PhD
University of Michigan Rogel Cancer Center, Ann Arbor, MI
Neelima Denduluri, MD
US Oncology Research, Virginia Cancer Specialists, Arlington, VA
Denise Yardley, MD
Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN
Yao Wang, MD
Pfizer Inc., New York, NY
Lillian Shahied Arruda, PhD
Pfizer Inc., New York, NY
Iulia C. Tudor, PhD
Pfizer Inc., San Francisco, CA
Eric Gauthier, PharmD, PhD
Pfizer Inc., San Francisco, CA
Akos Czibere, MD, PhD
Pfizer Inc., Cambridge, MA
Jennifer K. Litton, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Sara A. Hurvitz, MD
University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA

Background: Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer. Approval was based on results from the Phase 3 EMBRACA trial comparing efficacy and safety of talazoparib (1 mg/day) to physician’s choice of therapy ([PCT]; capecitabine, eribulin, gemcitabine, or vinorelbine) in patients with HER2-negative gBRCA1/2mut locally advanced/metastatic breast cancer.

Objectives: The purpose of this analysis was to describe efficacy and safety outcomes of talazoparib vs PCT in US patients included in the pivotal EMBRACA study.

Methods: Clinical findings from US patients enrolled in EMBRACA were analyzed. Patient characteristics, progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), and safety/adverse events (AEs) were among the parameters assessed.

Results: Of 431 randomized patients, 156 patients (36%) were from the US (talazoparib: 99 patients; PCT: 57 patients). Patient characteristics were balanced, although a higher percentage in the talazoparib arm had more poor prognostic features (e.g. triple-negative breast cancer, disease-free interval <12 months, and more disease sites). A total of 53 patients (53.5%) had hormone receptor (HR)+ breast cancer in the talazoparib arm and 37 patients (64.9%) had HR+ breast cancer in the PCT arm. Talazoparib improved PFS (median 9.0 [95% confidence interval (CI), 7.0-12.9] months) vs PCT (median 5.8 [95% CI, 4.2-6.7] months); hazard ratio (HR [95% CI]), 0.5 (0.3-0.7). ORR occurred in 51 patients (63.0%) receiving talazoparib and 11 patients (24.4%) receiving PCT. CBR was 68.7% (95% CI, 58.6-77.6) for talazoparib and 33.3% (95% CI, 21.4-47.1) for PCT; odds ratio (95% CI), 4.7 (2.2-10.6). Median duration of response was 5.0 months and 3.1 months for talazoparib and PCT, respectively. The most common AEs in the talazoparib arm included anemia, neutropenia, thrombocytopenia, fatigue, nausea, alopecia, and headache; hematologic grade 3/4 AEs occurred more often than nonhematologic AEs. Six out of 99 (6.1%) patients in the talazoparib arm and 6/43 (14.0%) patients in the PCT arm discontinued treatment.

Conclusions: In US patients with HER2-negative gBRCA1/2mut locally advanced/metastatic breast cancer, talazoparib demonstrated significant improvements in outcomes vs PCT with a manageable safety profile.

Note: © 2019 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2019 ASCO Annual Meeting. All rights reserved.

Clinical trial identification: NCT01945775

Funding: This study was sponsored by Medivation, which was acquired by Pfizer in September 2016.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State